Gulf International Bank UK Ltd Boosts Stake in Illumina, Inc. (NASDAQ:ILMN)

Gulf International Bank UK Ltd increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 0.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 45,100 shares of the life sciences company’s stock after buying an additional 60 shares during the period. Gulf International Bank UK Ltd’s holdings in Illumina were worth $7,825,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Aperio Group LLC raised its position in shares of Illumina by 23.5% in the second quarter. Aperio Group LLC now owns 46,023 shares of the life sciences company’s stock valued at $7,986,000 after buying an additional 8,757 shares during the period. Louisiana State Employees Retirement System raised its position in shares of Illumina by 1.1% in the second quarter. Louisiana State Employees Retirement System now owns 9,100 shares of the life sciences company’s stock valued at $1,579,000 after buying an additional 100 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Illumina by 13.7% in the second quarter. Nisa Investment Advisors LLC now owns 7,040 shares of the life sciences company’s stock valued at $1,235,000 after buying an additional 850 shares during the period. LS Investment Advisors LLC raised its position in shares of Illumina by 3.5% in the second quarter. LS Investment Advisors LLC now owns 3,358 shares of the life sciences company’s stock valued at $583,000 after buying an additional 115 shares during the period. Finally, Windward Capital Management Co. CA raised its position in shares of Illumina by 1.4% in the second quarter. Windward Capital Management Co. CA now owns 23,758 shares of the life sciences company’s stock valued at $4,122,000 after buying an additional 333 shares during the period. Institutional investors own 93.73% of the company’s stock.

Illumina, Inc. (NASDAQ ILMN) traded up 0.45% during trading on Friday, reaching $172.75. 1,411,426 shares of the company were exchanged. The company’s 50-day moving average price is $175.68 and its 200-day moving average price is $170.24. The stock has a market capitalization of $25.22 billion, a P/E ratio of 34.96 and a beta of 0.84. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $189.48.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.64. The company had revenue of $598 million during the quarter, compared to analysts’ expectations of $590.51 million. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.71 EPS. On average, equities analysts forecast that Illumina, Inc. will post $3.63 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “[[title]]” was originally reported by [[site]] and is owned by of [[site]]. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at [[permalink]].

Several research analysts recently issued reports on the stock. Barclays PLC reiterated a “hold” rating and issued a $150.00 target price on shares of Illumina in a research report on Wednesday. Morgan Stanley reiterated an “underweight” rating and issued a $122.00 target price (up from $115.00) on shares of Illumina in a research report on Monday, July 10th. BidaskClub lowered shares of Illumina from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. Finally, Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 target price for the company in a research report on Monday, July 3rd. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $166.54.

In other news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $184.14, for a total value of $3,682,800.00. Following the completion of the sale, the director now owns 539,176 shares in the company, valued at approximately $99,283,868.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Charles Dadswell sold 1,609 shares of the business’s stock in a transaction dated Wednesday, May 3rd. The shares were sold at an average price of $187.07, for a total transaction of $300,995.63. Following the completion of the sale, the senior vice president now owns 10,936 shares of the company’s stock, valued at approximately $2,045,797.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 125,248 shares of company stock valued at $22,281,673. 1.60% of the stock is owned by corporate insiders.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).